Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
6.79
-0.01 (-0.15%)
At close: Nov 28, 2025, 1:00 PM EST
6.84
+0.05 (0.74%)
After-hours: Nov 28, 2025, 4:25 PM EST
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $17.15M in the quarter ending September 30, 2025, a decrease of -58.84%. This brings the company's revenue in the last twelve months to $97.60M, down -39.15% year-over-year. In the year 2024, Arcturus Therapeutics Holdings had annual revenue of $152.31M, down -8.69%.
Revenue (ttm)
$97.60M
Revenue Growth
-39.15%
P/S Ratio
1.89
Revenue / Employee
$554,551
Employees
176
Market Cap
192.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ARCT News
- 5 days ago - Arcturus Therapeutics to Attend Upcoming Investor Conference - Business Wire
- 19 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress - Business Wire
- 25 days ago - Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025 - Business Wire
- 5 weeks ago - Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture - Benzinga
- 5 weeks ago - Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results - Invezz
- 5 weeks ago - Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire